ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion
APL2-PNH-209
Phase 2 small_molecule active
Quick answer
ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion for Paroxysmal Nocturnal Hemoglobinuria is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Paroxysmal Nocturnal Hemoglobinuria
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active